343 related articles for article (PubMed ID: 29927689)
1. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
[TBL] [Abstract][Full Text] [Related]
2. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
3. The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation.
Wang L; Babikir H; Müller S; Yagnik G; Shamardani K; Catalan F; Kohanbash G; Alvarado B; Di Lullo E; Kriegstein A; Shah S; Wadhwa H; Chang SM; Phillips JJ; Aghi MK; Diaz AA
Cancer Discov; 2019 Dec; 9(12):1708-1719. PubMed ID: 31554641
[TBL] [Abstract][Full Text] [Related]
4. Identification of Global DNA Methylation Signatures in Glioblastoma-Derived Cancer Stem Cells.
Lee EJ; Rath P; Liu J; Ryu D; Pei L; Noonepalle SK; Shull AY; Feng Q; Litofsky NS; Miller DC; Anthony DC; Kirk MD; Laterra J; Deng L; Xin HB; Wang X; Choi JH; Shi H
J Genet Genomics; 2015 Jul; 42(7):355-71. PubMed ID: 26233891
[TBL] [Abstract][Full Text] [Related]
5. An epigenetic biomarker panel for glioblastoma multiforme personalized medicine through DNA methylation analysis of human embryonic stem cell-like signature.
Chiang JH; Cheng WS; Hood L; Tian Q
OMICS; 2014 May; 18(5):310-23. PubMed ID: 24601786
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal and Proneural Subtypes of Glioblastoma Disclose Branching Based on GSC Associated Signature.
Steponaitis G; Tamasauskas A
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066996
[TBL] [Abstract][Full Text] [Related]
7. Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival.
Sana J; Busek P; Fadrus P; Besse A; Radova L; Vecera M; Reguli S; Stollinova Sromova L; Hilser M; Lipina R; Lakomy R; Kren L; Smrcka M; Sedo A; Slaby O
Sci Rep; 2018 Feb; 8(1):2836. PubMed ID: 29434344
[TBL] [Abstract][Full Text] [Related]
8. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
9. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
10. Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues.
Zhou D; Alver BM; Li S; Hlady RA; Thompson JJ; Schroeder MA; Lee JH; Qiu J; Schwartz PH; Sarkaria JN; Robertson KD
Genome Biol; 2018 Mar; 19(1):43. PubMed ID: 29587824
[TBL] [Abstract][Full Text] [Related]
11. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
[No Abstract] [Full Text] [Related]
12. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
14. Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma.
Lin CA; Rhodes CT; Lin C; Phillips JJ; Berger MS
Cell Cycle; 2017 Apr; 16(8):765-775. PubMed ID: 28278055
[TBL] [Abstract][Full Text] [Related]
15. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
Mala U; Baral TK; Somasundaram K
BMC Cancer; 2022 Jun; 22(1):642. PubMed ID: 35690717
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Riva G; Butta V; Cilibrasi C; Baronchelli S; Redaelli S; Dalprà L; Lavitrano M; Bentivegna A
Oncol Rep; 2016 May; 35(5):2811-24. PubMed ID: 26986767
[TBL] [Abstract][Full Text] [Related]
18. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.
Luedi MM; Singh SK; Mosley JC; Hassan ISA; Hatami M; Gumin J; Andereggen L; Sulman EP; Lang FF; Stueber F; Fuller GN; Colen RR; Zinn PO
J Neurosurg; 2018 Dec; 129(6):1446-1455. PubMed ID: 29328002
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
Wakimoto H; Mohapatra G; Kanai R; Curry WT; Yip S; Nitta M; Patel AP; Barnard ZR; Stemmer-Rachamimov AO; Louis DN; Martuza RL; Rabkin SD
Neuro Oncol; 2012 Feb; 14(2):132-44. PubMed ID: 22067563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
